Researchers presented the largest prospective pooled dataset to date linking multiparameter flow cytometry minimal residual disease (MRD) status with overall survival in acute myeloid leukemia, strengthening MRD’s case as a surrogate endpoint. Presenters argued MRD-negative status prior to consolidation predicts longer survival and could support accelerated regulatory approvals, mirroring precedent in ALL and multiple myeloma. Investigators and industry speakers noted that validating MRD as an intermediate endpoint could shorten AML development timelines and alter trial design and regulatory interactions.